title: The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders.
abstract: Lisdexamfetamine dimesylate (LDX) is a long-acting oral prodrug stimulant. It is inactive until enzymatically hydrolyzed in the blood to active D-amphetamine. The pharmacological action of this compound involves blocking norepinephrine (NE) and dopamine reuptake into presynaptic neurons and promoting the release of NE and dopamine into the extraneuronal space. LDX has been approved for treating ADHD, which is the most common psychiatric disorder in children and adolescents. Also, LDX has been proposed for other psychiatric conditions related with dopaminergic and NE CNS. LDX is the first long-acting oral prodrug indicated for the treatment of ADHD in children (6-12 years), adolescents (13-17 years) and in adults in the USA and Canada, whereas, in Europe, LDX is licensed in several countries for the treatment of children and adolescents with ADHD who have had a clinically inadequate response to methylphenidate. This article covers the most important pharmacological aspects of LDX as well as data on the efficacy, tolerability and safety of this long-acting amphetamine prodrug collected from clinical studies recently published in the literature.
authors.affiliation: Department of Psychiatry, Outpatient Drug Clinic, Vall d'Hebron University Hospital-Barcelona Pubic Health Agency (ASPB), Passeig Vall d'Hebron, 119-129, E-08035 Barcelona, Spain.
authors.forename: Carlos
authors.initials: C
authors.lastname: Roncero
authors.forename: F Javier
authors.initials: FJ
authors.lastname: Álvarez
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D003913:Dextroamphetamine / Q000627:therapeutic use*; D006801:Humans; D000069478:Lisdexamfetamine Dimesylate; D001523:Mental Disorders / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D000069478:Lisdexamfetamine Dimesylate; D003913:Dextroamphetamine
keywords: ADHD; efficacy; lisdexamfetamine dimesylate; prodrug; safety; tolerability